Phase I Clinical Trial Of ImmuFact IMP321 In Pancreatic Cancer Will Be Carried Out At Washington University In Saint Louis

Immutep S.A. announced today that the FDA, after review of the Investigational New Drug Application (IND), has allowed the administration of IMP321 in cancer patients in a Phase I trial conducted by Dr. William G. Hawkins at the Washington University School of Medicine in Saint Louis (MO).

More: continued here

Filed under: Prostate on October 27th, 2008